Business Segments · R&D
Life Sciences: — R&D
STERIS Life Sciences: — R&D increased by 3.7% to $2.80M in Q4 2025 compared to the prior quarter.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ3 2024
Last reportedQ4 2025
Rolls up toR&D
How to read this metric
Higher spending signals a focus on long-term innovation and new product pipelines, while lower spending may indicate a shift toward cost optimization or a mature product cycle.
Detailed definition
This metric tracks the investment in innovation, product development, and engineering specifically dedicated to the Life...
Peer comparison
Standard R&D expense reporting for business segments in the life sciences and medical device sectors.
Metric ID:
ste_segment_life_sciences_research_and_developmentHistorical Data
4 periods
| Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|
| Value | $2.10M | $2.40M | $2.70M | $2.80M |
| QoQ Change | — | +14.3% | +12.5% | +3.7% |
| YoY Change | — | — | +28.6% | +16.7% |
Range$2.10M – $2.80M
Avg YoY Growth+22.6%
Median YoY Growth+22.6%
Current Streak3+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is STERIS's life sciences: — r&d?
- STERIS (STE) reported life sciences: — r&d of $2.80M in Q4 2025.
- What does life sciences: — r&d mean?
- Expenditures on research and product development for the Life Sciences segment.